<< Read Full Article
<< Read Full Article
InterMune Up Despite So-So Hep C Data
- Loading Comments...
Updated from 10:39 a.m. EST
SAN FRANCISCO -- InterMune(ITMN Quote) has moved forward with development of a new hepatitis C drug, dubbed ITMN-191, on the premise that it will be more potent and more convenient to administer than a similar drug from Vertex Pharmaceuticals(VRTX Quote).
But new data released Monday morning on ITMN-191 doesn't completely live up to that billing.
A 600 mg dose of ITMN-191 given twice daily and combined with the current standard of care therapy for hepatitis C reduced the amount of virus below detectable levels in 13% of patients treated for 14 days. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,452.00 | 1,107.93 | 2,201.05 | 36.03 |
Oil *
72.08
|
|
DOWN
49.05
|
DOWN
6.18
|
DOWN
11.05
|
UP
0.57
|
10 Yr
3.60%
SPDR Gold
110.21
|
|
-0.47%
|
-0.55%
|
-0.50%
|
+1.61%
|
Data delayed 20 minutes |


Connect with TheStreet